MSLE: Satellos Bioscience Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
26 institutions reported holding $59.58M of Satellos Bioscience Inc. on Form 13F (31 the quarter before). 2 opened a new position and 7 sold out. Shares held by institutions: +2%.
| Largest holders | Shares | Value |
|---|---|---|
| FRANKLIN RESOURCES INC | 938,666 | $7.23M |
| Siren, L.L.C. | 892,074 | $6.94M |
| Vivo Capital, LLC | 813,666 | $6.33M |
| Point72 Asset Management, L.P. | 682,700 | $5.31M |
| SPHERA FUNDS MANAGEMENT LTD. | 652,590 | $5.07M |
| Woodline Partners LP | 500,432 | $3.89M |
| Stonepine Capital Management, LLC | 491,624 | $3.72M |
| MONTANOVA CAPITAL, LLC | 475,000 | $3.69M |
| Avidity Partners Management LP | 387,769 | $3.01M |
| Saturn V Capital Management LP | 350,000 | $2.72M |
Clinical trial readouts
2 Phase 2 or 3 trials by Satellos Bioscience Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03-31 (est.) | SAT-3247 | Duchenne Muscular Dystrophy | Phase 2 | 51 | Enrollment complete | NCT07287189 |
| 2027-09-30 (est.) | SAT-3247 | Duchenne Muscular Dystrophy (DMD) | Phase 2 | 30 | Enrolling by invitation | NCT06867107 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.